2024
Missed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases
Parchinski K, Neirinckx V, Frank C, Di Paola A, Tarfa A, Shenoi S, Vander WyK B, Roth P, Ghantous T, Wegman M, Strong M, Levin F, Brady K, Nunes E, Litwin A, Springer S. Missed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases. Open Forum Infectious Diseases 2024, 11: ofae366. PMID: 39022389, PMCID: PMC11252843, DOI: 10.1093/ofid/ofae366.Peer-Reviewed Original Research
2023
Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non‐Clinicians
Di Paola A, Farabee D, Springer S. Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non‐Clinicians. Psychiatric Research And Clinical Practice 2023, 5: 78-83. PMID: 37711754, PMCID: PMC10499189, DOI: 10.1176/appi.prcp.20230022.Peer-Reviewed Original ResearchStimulant use disorderUse disordersSevere opioid use disorderMini International Neuropsychiatric InterviewDiagnostic assessmentOpioid use disorderDisorder assessmentInternational Neuropsychiatric InterviewDSM-IV criteriaHarm reduction interventionsNon-clinical staffTraditional diagnostic assessmentInternal consistencyDSM-5 versionValid measureOpioid dependenceOpioid misuseImmediate treatmentNeuropsychiatric InterviewOpioid epidemicDisorder modulesOverdose deathsReduction interventionsNon cliniciansRapid diagnosisCorrigendum to ‘Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder’ [J. Subst. Abuse Treat. vol. 142 (2022)/108852]
Lier A, Seval N, Vander Wyk B, Di Paola A, Springer S. Corrigendum to ‘Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder’ [J. Subst. Abuse Treat. vol. 142 (2022)/108852]. Journal Of Substance Use And Addiction Treatment 2023, 150: 209074. PMID: 37271717, DOI: 10.1016/j.josat.2023.209074.Peer-Reviewed Original ResearchThe relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
Parchinski K, Di Paola A, Wilson A, Springer S. The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV. Drug And Alcohol Dependence Reports 2023, 7: 100159. PMID: 37159815, PMCID: PMC10163604, DOI: 10.1016/j.dadr.2023.100159.Peer-Reviewed Original ResearchOpioid use disorderExtended-release naltrexoneXR-NTXUse disordersKaplan-Meier survival analysisHIV viral suppressionMajor depressive disorderPublic health priorityOpioid cravingViral suppressionOpioid useHIV outcomesLife scoresRetrospective studyStudy baselineDepressive disorderOdds ratioDecrease recurrenceHealth prioritySurvival analysisPWHLifetime incarcerationStudy periodMean timeDisorders
2022
Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder
Lier A, Vander Wyk B, Di Paola A, Springer S. Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder. Open Forum Infectious Diseases 2022, 9: ofac624. PMID: 36467300, PMCID: PMC9709708, DOI: 10.1093/ofid/ofac624.Peer-Reviewed Original ResearchOpioid use disorderHepatitis C virusHCV treatment ratesHIV serostatusUse disordersHepatitis C virus (HCV) care cascadeHCV viral load testingTreatment ratesHCV treatment uptakeProspective cohort studyInjection drug useViral load testingGreater reductionDrug use frequencyHCV testingCare cascadeHCV antibodiesHIV screeningCohort studyHIV statusTreatment uptakeEntire cohortMedication treatmentC virusSerostatusAssociation between Prescribers’ Perceptions of the Utilization of Medication for Opioid Use Disorder and Opioid Dependence Treatability
Adzrago D, Di Paola A, Zhu J, Betancur A, Wilkerson J. Association between Prescribers’ Perceptions of the Utilization of Medication for Opioid Use Disorder and Opioid Dependence Treatability. Healthcare 2022, 10: 1733. PMID: 36141345, PMCID: PMC9498711, DOI: 10.3390/healthcare10091733.Peer-Reviewed Original ResearchOpioid use disorderSubstance use disordersUse disordersUse of MOUDUtilization of medicationsPharmacy professionalsLogistic regression analysisProfessionals' perceptionsMultinomial logistic regression analysisRisk ratio (RR) valuesOpioid treatmentMean ageMOUDPrescriber perceptionsMOUD servicesReplacement drugsSociodemographic characteristicsPatient accessibilityDisordersMedicationsPatientsRegression analysisMedical professionalsAbstinenceParticipantsMaintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder
Lier AJ, Seval N, Vander Wyk B, Di Paola A, Springer SA. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder. Journal Of Substance Use And Addiction Treatment 2022, 142: 108852. PMID: 35988513, PMCID: PMC9509444, DOI: 10.1016/j.jsat.2022.108852.Peer-Reviewed Original ResearchConceptsInjection opioid useOpioid use disorderHepatitis C virusOpioid useXR-NTXOpioid injectionUse disordersDouble-blind placebo-controlled trialExtended-release naltrexonePlacebo-controlled trialCopies/mLIntravenous opioid useTransmission of HIVJustice-involved populationsJustice-involved participantsInjection equipmentHigh treatment groupJustice-involved personsHCV antibodiesHIV RNAPlacebo groupTreat analysisC virusInjection useJustice-involved individualsFactors associated with HIV testing and treatment among young Black MSM and trans women in three jail systems
Antos N, Flores R, Harawa N, Del Vecchio N, Issema R, Fujimoto K, Khanna A, Di Paola A, Schneider J, Hotton A. Factors associated with HIV testing and treatment among young Black MSM and trans women in three jail systems. AIDS Care 2022, 35: 123-130. PMID: 35848452, PMCID: PMC10359835, DOI: 10.1080/09540121.2022.2094312.Peer-Reviewed Original ResearchConceptsHIV testingViral suppressionHigher oddsMultivariable logistic regressionYoung Black MSMFull multivariable modelDuration of incarcerationMultivariable modelLower oddsBinge drinkingBlack MSMTransgender womenLogistic regressionJail systemOddsBlack menBMSMWomenMenTreatmentTrans womenLos AngelesProtective custodyLevel factorsIncarcerationGender differences among persons entering medication treatment for opioid use disorder in the community
Di Paola A, Taweh N, Biondi BE, Forray A, Frank CA, Shaw A, Springer SA. Gender differences among persons entering medication treatment for opioid use disorder in the community. American Journal On Addictions 2022, 31: 390-395. PMID: 35652902, PMCID: PMC9463117, DOI: 10.1111/ajad.13304.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersQuality of lifeDSM-5 diagnosisPosttraumatic stress disorderOpioid relapseMedication useMedication historyMedication treatmentPsychiatric comorbidityPsychiatric medicationsHigh riskMOUDDepression severityGreater prevalenceGender differencesBaseline assessmentPsychological QoL.Disorder screeningStress disorderMultidisciplinary programGeneralized anxietyWomenMedicationsDisordersStudy protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons
Springer SA, Nijhawan AE, Knight K, Kuo I, Di Paola A, Schlossberg E, Frank CA, Sanchez M, Pankow J, Proffitt RP, Lehman W, Pulitzer Z, Thompson K, Violette S, Harding KK. Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons. BMC Infectious Diseases 2022, 22: 380. PMID: 35428213, PMCID: PMC9013109, DOI: 10.1186/s12879-022-07354-x.Peer-Reviewed Original ResearchConceptsJustice-involved individualsAntiretroviral treatmentHIV preventionUse disordersStudy participantsStimulant useSubstance use disorder servicesCommunity-based HIVPost-release interventionsPrimary implementation outcomeHIV viral loadPre-exposure prophylaxisOpioid use disorderTreatment of HIVHIV risk behaviorsRisk of HIVSubstance use disordersHigh-risk communitiesHybrid type 1Justice-involved personsHCV testingLinkage interventionHIV careSecondary outcomesART adherence
2021
Sexual Violence and Chemsex among Substance-Using Sexual and Gender Minorities in Texas
Wilkerson J, Di Paola A, Nieto D, Schick V, Latini D, Braun-Harvey D, Zoschke I, McCurdy S. Sexual Violence and Chemsex among Substance-Using Sexual and Gender Minorities in Texas. Substance Use & Misuse 2021, 56: 2141-2150. PMID: 34550052, DOI: 10.1080/10826084.2021.1975743.Peer-Reviewed Original ResearchConceptsSexual violenceSexual minority menGender minoritiesMinority menSexual exploitationSex partiesSexual experienceNotion of consentViolence emergeSexualized environmentRelationship violenceSexual identityQualitative interviewsViolenceFurther conceptualizationMinorityUse of methamphetaminePartiesChemsexSurvey participantsSubstance useOnline surveyContextExperienceInterviews
2020
Covariates of hazardous alcohol use among sexual and gender minorities in Texas: Identifying the most vulnerable
Wilkerson J, Di Paola A, McCurdy S, Schick V. Covariates of hazardous alcohol use among sexual and gender minorities in Texas: Identifying the most vulnerable. Addictive Behaviors 2020, 105: 106327. PMID: 32044679, DOI: 10.1016/j.addbeh.2020.106327.Peer-Reviewed Original ResearchConceptsHazardous drinkersHistory of incarcerationHazardous drinkingLogistic regression modelsMultivariate logistic regression modelMultiple logistic regression modelNon-hazardous drinkersHazardous alcohol useRegression modelsCriminal justice involvementAlcohol useMental healthSubstance useDrinkersDrinkingPrevalenceJustice involvementGender minority personsDepressionCovariatesSGM adolescentsMarijuanaOnline surveyMinority personsOpioids
2019
A modeling framework to inform preexposure prophylaxis initiation and retention scale-up in the context of 'Getting to Zero' initiatives.
Khanna A, Schneider J, Collier N, Ozik J, Issema R, di Paola A, Skwara A, Ramachandran A, Webb J, Brewer R, Cunningham W, Hilliard C, Ramani S, Fujimoto K, Harawa N. A modeling framework to inform preexposure prophylaxis initiation and retention scale-up in the context of 'Getting to Zero' initiatives. AIDS 2019, 33: 1911-1922. PMID: 31490212, PMCID: PMC6760326, DOI: 10.1097/qad.0000000000002290.Peer-Reviewed Original ResearchConceptsPrEP initiationHIV incidenceYoung Black MSMAgent-based network modelSerodiscordant partnershipsBlack MSMEffective PrEP implementationHigh HIV incidenceHIV-negative individualsNew HIV infectionsPrEP initiatorsPrEP interventionsProphylaxis initiationAntiretroviral therapyPreexposure prophylaxisPrEP implementationPrEP uptakeHIV infectionPrEP useRetention interventionsMean durationCombination interventionsInitiation interventionIncidenceIntervention
2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomesSubstance Use, Mental Health, HIV Testing, and Sexual Risk Behavior Among Men Who Have Sex With Men in the State of Maharashtra, India.
Wilkerson J, Di Paola A, Rawat S, Patankar P, Rosser B, Ekstrand M. Substance Use, Mental Health, HIV Testing, and Sexual Risk Behavior Among Men Who Have Sex With Men in the State of Maharashtra, India. AIDS Education And Prevention 2018, 30: 96-107. PMID: 29688773, PMCID: PMC6214349, DOI: 10.1521/aeap.2018.30.2.96.Peer-Reviewed Original ResearchConceptsIllicit substance useSubstance usePolysubstance useHazardous drinkingIntimate partner violenceSexual partnersCondomless anal sexMental health servicesPublic health interventionsSexual risk behaviorsHIV testingOverall prevalenceAnal sexHealth servicesHealth interventionsRisk behaviorsIllicit substancesMental healthMenSexPartner violenceDrinkingParticipantsOnline surveyHIV
2017
Corrigendum to “Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community” [Contemp. Clin. Trials (2014) 209–218]
Springer SA, Altice FL, Herme M, Di Paola A. Corrigendum to “Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community” [Contemp. Clin. Trials (2014) 209–218]. Contemporary Clinical Trials 2017, 57: 98. PMID: 28341227, DOI: 10.1016/j.cct.2017.03.008.Peer-Reviewed Original ResearchCorrigendum to ‘An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone’ [Journal of Substance Abuse Treatment 47 (2014) 35–40]
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. Corrigendum to ‘An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone’ [Journal of Substance Abuse Treatment 47 (2014) 35–40]. Journal Of Substance Use And Addiction Treatment 2017, 77: 44. PMID: 28476270, PMCID: PMC5458355, DOI: 10.1016/j.jsat.2017.03.008.Peer-Reviewed Original ResearchExtended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderFirst heavy drinking dayExtended-release naltrexoneXR-NTXDrinking daysPlacebo groupAlcohol consumptionDrinks/drinking dayPlacebo-controlled trialSerious adverse eventsDrinks/daySignificant differencesMonthly injectionsAdverse eventsHIV diseaseHIV outcomesTreatment armsAlcohol scoresMAIN OUTCOMEAlcohol consumption scoresUse disordersImprovement scoresDrinking outcomesNaltrexone
2016
Erratum to “Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system” [Drug Alcohol Depend. 157 (2015) 158–165]
Springer S, Brown S, Di Paola A. Erratum to “Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system” [Drug Alcohol Depend. 157 (2015) 158–165]. Drug And Alcohol Dependence 2016, 161: 372. PMID: 28463553, PMCID: PMC4871258, DOI: 10.1016/j.drugalcdep.2016.02.009.Peer-Reviewed Original Research